TY - JOUR
T1 - Isolated hemopericardium after initiation of rivaroxaban
T2 - Implications and potential mechanisms
AU - Mehta, Adwait
AU - Burkland, David
AU - Mathuria, Nilesh
N1 - Publisher Copyright:
© A. Mehta et al., 2019.
PY - 2019
Y1 - 2019
N2 - Direct oral anticoagulants have become increasingly used for atrial fibrillation and venothromboembolic disease. Thus far, there have been a few published cases of pericardial effusion associated with rivaroxban. However, there has been little published regarding the effects of concurrent medications and their effect on the cytochrome enzyme systems involved in rivaroxaban metabolism. We present a case of a 76-year-old female who develops a spontaneous haemopericardium after initiating rivaroxaban. After thorough medical reconciliation, we offer pharmacokinetic mechanisms that may have contributed to the haemopericardium. This case demonstrates the importance of reviewing patients medication lists and utilizing basic pharmacokinetics to prevent adverse events.
AB - Direct oral anticoagulants have become increasingly used for atrial fibrillation and venothromboembolic disease. Thus far, there have been a few published cases of pericardial effusion associated with rivaroxban. However, there has been little published regarding the effects of concurrent medications and their effect on the cytochrome enzyme systems involved in rivaroxaban metabolism. We present a case of a 76-year-old female who develops a spontaneous haemopericardium after initiating rivaroxaban. After thorough medical reconciliation, we offer pharmacokinetic mechanisms that may have contributed to the haemopericardium. This case demonstrates the importance of reviewing patients medication lists and utilizing basic pharmacokinetics to prevent adverse events.
KW - Direct oral anticoagulant
KW - Peericardial effusion
KW - Rivaroxaban
UR - http://www.scopus.com/inward/record.url?scp=85092215956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092215956&partnerID=8YFLogxK
U2 - 10.4081/cp.2019.1096
DO - 10.4081/cp.2019.1096
M3 - Article
AN - SCOPUS:85092215956
VL - 9
SP - 4
EP - 5
JO - Clinics and Practice
JF - Clinics and Practice
SN - 2039-7283
IS - 1
M1 - 1096
ER -